mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK

Oncotarget

Volumn 7, Issue 23, 2016, Pages 35188-35198

  Liu, Peng ^a   Ye, Feng ^a   Xie, Xinhua ^a   Li, Xing ^a   Tang, Hailin ^a   Li, Shuaijie ^a   Huang, Xiaojia ^a   Song, Cailu ^a   Wei, Weidong ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

AMPK; mir 101 3p; Triple negative breast cancer; Tumor metabolism

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MICRORNA 101; ADENYLATE KINASE; MICRORNA; MIRN103 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENERAL ASPECTS OF DISEASE; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; METABOLIC REGULATION; MIDDLE AGED; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR METABOLISM; TUMOR XENOGRAFT; UPREGULATION; AGED; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY;

ADENYLATE KINASE; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84973661688     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9072     Document Type: Article

References (39)

1. Siegel RL, Miller KD and Dvm AJ. Cancer Statistics, 2015. CA Cancer J Clin. 2014; 65:5-29
2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB and Hayes DF. Revision of the American Joint Committee on Cancer staging system for breast cancer. Journal of Clinical Oncology. 2002; 20:3628-3636
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK and Edmiston S. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295:2492-2502
4. Lachapelle J and Foulkes WD. Triple-negative and basallike breast cancer: implications for oncologists. Current Oncology. 2011; 18:161-164
5. Rebecca D, Maureen T, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Ellen R, Ping S and Narod SA. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research. 2007; 13:4429-4434
6. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938-1948
7. Chacon RD and Costanzo. Triple-negative breast cancer. Drugs. 2010; 12:1-9
8. Frankel LB. microRNA-101 is a potent inhibitor of autophagy. Embo Journal. 2011; 30:4628-4641
9. Peter FJJG. (2010). The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2. Cancer Res. pp. 2700-2700
10. Friedman JM, Jones PA and Gangning L. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the Polycomb group protein EZH2 in cancer. Cell Cycle. 2009; 8:2313-2314
11. Smits M, Mir S, Niers J, Marquez V, Tannous B, Cloos J, Noske D and Wurdinger T. MicroRNA-101 targets EZH2 and controls angiogenesis in glioblastoma multiforme. Cancer Research. 2009; 69
12. Malek and Nisar P. Another myc in the wall: microRNA-101 controls important functions in liver cancer formation. Hepatology. 2014; 59:1676-1677
13. Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT, Califano J, Wu TC and Pang X. Enforced Expression of miR-101 Inhibits Prostate Cancer Cell Growth by Modulating the COX-2 Pathway In Vivo. Cancer Prevention Research. 2011; 4:1073-1083
14. Rui W, Hong-Bin W, Chan Juan H, Yi C, Xiao-Chen H, Yi H, Fei-Feng L, Hong-Fei X and Xu M. MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1. Plos One. 2012; 7:e46173-e46173
15. Varambally S and Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322:1695-1699
16. Antonio S, Cristiana G, Pasquale S, Paola P, Giulia P, Giorgia L, Enzo S, Maria Abbondanza P, Guido B and Vittorio T. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009; 315:1439-1447
17. Hang S, Jian-Rong Y, Teng X, Jun H, Li X, Yunfei Y and Shi-Mei Z. MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research. 2009; 69:1135-1142
18. Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X and Lin X. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015; 6:20070-83. doi: 10.18632/oncotarget.4039
19. Garber K. Energy Boost: The Warburg Effect Returns in a New Theory of Cancer. Journal of the National Cancer Institute. 2004; 96:1805-1806
20. Vladimir G, Boris Z and Sten O. The Warburg effect and mitochondrial stability in cancer cells. Molecular Aspects of Medicine. 2010; 31:60-74
21. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM and Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Molecular Biology Reports. 2015; 42:841-851
22. Li XB, Gu JD and Zhou QH. Review of aerobic glycolysis and its key enzymes -new targets for lung cancer therapy. Thoracic Cancer. 2014; 6
23. Brandon F, Vincent EE, Poffenberger MC and Jones RG. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Letters. 2015; 356:165-170
24. Novikova DS, Garabadzhiu AV, Melino G, Barlev NA and Tribulovich VG. AMP-Activated Protein Kinase: Structure, Function, and Role in Pathological Processes. Biochemistry Biochemistry (Mosc). 2015; 80:127-144
25. Jeon SM and Hay N. The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Archives of Pharmacal Research. 2015; 38:346-357
26. Ha J, Guan KL and Kim J. AMPK and autophagy in glucose/glycogen metabolism. Molecular Aspects of Medicine. 2015. 2015; 46:46-62
27. Pineda C, Ramanathan S, Fontacer K, Weon J, Potts M, Ou YH, White M and Potts PR. Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase. Cell. 2015; 160:715-728
28. Brown KA, Samarajeewa NU and Simpson ER. Endocrinerelated cancers and the role of AMPK. Molecular & Cellular Endocrinology. 2012; 366:170-179
29. Zhang YL, Guo H, Zhang CS, Lin SY, Yin Z, Peng Y, Luo H, Shi Y and Lian G. AMP as a Low-Energy Charge Signal Autonomously Initiates Assembly of AXIN-AMPK-LKB1 Complex for AMPK Activation. Cell Metabolism. 2013; 18:546-55
30. Hardie DG. Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? Clinical Cancer Research. 2015; 21:3836-3840
31. Zadra G, Batista JL and Loda M. Dissecting the Dual Role of AMPK in Cancer: from Experimental to Human Studies. Molecular Cancer Research Mcr. 2015; 13
32. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006; 6:857-866
33. Huiping L. MicroRNAs in breast cancer initiation and progression. Cellular & Molecular Life Sciences. 2012; 69:3587-3599
34. Ana Paula V, Andrade BM, Fernanda V, Juliana C, Pinto LFR, Marisa Mariayer B, Rossana C, Adriana CB, Fernando S and Mario V. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. European Journal of Endocrinology. 2013; 169:521-528
35. Li C, Liu VW, Chiu PM, Chan DW and Ngan HY. Overexpressions of AMPK subunits in ovarian carcinomas with significant clinical implications. Bmc Cancer. 12:1-8
36. Sanli T, Linher-Melville K, Tsakiridis T and Singh G. Sestrin2 Modulates AMPK Subunit Expression and Its Response to Ionizing Radiation in Breast Cancer Cells. Plos One. 1982; 43
37. Lipovka Y, Chen H, Vagner J, Price TJ, Tsao TS and Konhilas JP. Estrogen receptors interact with the alpha catalytic subunit of AMP-activated protein kinase. Bioscience Reports. 2015; 35
38. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA and Hardie DG. Histological evaluation of AMPK signalling in primary breast cancer. Bmc Cancer. 2009; 9:243
39. Feng Y, Tang H, Liu Q, Xie X, Wu M, Liu X, Bo C and Xie X. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. Journal of Translational Medicine. 12:1-10